eli lilly and company mounjaro - Search News

News

Eli Lilly sues Mochi Health and others

CNBC on MSN · 3d

Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its diabetes drug Mounjaro.

Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.

Eli Lilly Files Slew of Lawsuits Over Zepbound and Mounjaro

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and Zepbound, which treats obesity.

8d

Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

1d

Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...

Houston Public Media3d

Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

1don MSN

Is Eli Lilly and Company (LLY) the Best Stock to Invest in for Long Term?

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at ...

24/7 Wall St. on MSN1d

Eli Lilly Will Be the Next $1 Trillion Stock

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

1d

Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results